IL6 and neutropenia: JAK inhibitors including tofacitinib and baricitinib, which target signaling down-stream of cytokine receptors including IL-6, interferon-α and -γ, and GM-CSF receptors, are clinically effective in treating RA (85, 86) although many patients report transient neutropenia and increased infections.